NANOVIRICIDES, INC. (NNVC) - Dilution Analysis

8-K filing: NanoViricides, Inc. completed a registered direct offering of common stock and warrants, resulting in aggregate gross proceeds of approximately $2.0 million. ($2.0M proceeds)

S-3 filing: This S-3 filing relates to the offer and resale of common stock issuable upon the exercise of Series A and Series B Common Stock Purchase Warrants.

8-K filing: NanoViricides, Inc. completed a registered direct offering and concurrent private placement, selling 1,970,000 shares of common stock and pre-funded warrants to purchase up to 1,601,429 shares of common stock to an institutional investor, along with warrants to purchase additional shares, resulting in gross proceeds of approximately $6.0 million.

10-Q filing | 17.1M shares outstanding

10-K filing | 17.4M shares outstanding

10-Q filing | 16.0M shares outstanding

10-Q filing | 14.6M shares outstanding

10-Q filing | 13.7M shares outstanding

10-K filing | 11.9M shares outstanding

10-Q filing | 11.8M shares outstanding

8-K filing: NanoViricides, Inc. amended its License Agreement with TheraCour Pharma, Inc. regarding milestone payments, extending a line of credit with Dr. Anil R. Diwan, and suspending advance payments to TheraCour.

10-Q filing | 11.7M shares outstanding

10-Q filing | 11.7M shares outstanding

10-K filing | 11.6M shares outstanding

10-Q filing | 11.6M shares outstanding

S-3/A filing: This S-3/A filing details the estimated costs and expenses associated with the potential issuance and distribution of an assumed $150,000,000 of securities, and it includes information regarding the indemnification of directors and officers.

S-3 filing: Nanoviricides, Inc. files an S-3 form for a mixed shelf offering of common stock, preferred stock, and debt securities, warrants and units up to $150,000,000.

10-Q filing | 11.6M shares outstanding

10-Q filing | 11.6M shares outstanding

10-K filing | 11.5M shares outstanding

10-Q filing | 11.5M shares outstanding

10-Q filing | 11.5M shares outstanding

10-Q filing | 11.5M shares outstanding

10-K filing | 11.5M shares outstanding

8-K filing: NanoViricides, Inc. entered into a License Agreement with TheraCour Pharma, Inc. for an exclusive, worldwide license for further development of treatments for coronavirus derived human infections, involving milestone payments in cash and Series A Convertible Preferred Stock.

10-Q filing | 11.5M shares outstanding

10-Q filing | 10.7M shares outstanding

10-Q filing | 10.7M shares outstanding

10-K filing | 3.8M shares outstanding

8-K filing: NanoViricides, Inc. completed an underwritten public offering on July 10, 2020, selling 1,575,342 shares of common stock at $7.30 per share, resulting in net proceeds of approximately $10.53 million for general corporate purposes. ($11.51M proceeds)

10-Q filing | 9.1M shares outstanding

8-K filing: NanoViricides, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 1,400,000 shares of common stock at $7.30 per share, with the offering closing on May 22, 2020, resulting in net proceeds of approximately $9.3 million. ($10.22M proceeds)

S-3 filing: Nanoviricides, Inc. files an S-3 form for a mixed shelf offering of common stock, preferred stock, and debt securities, warrants, and units for up to $150,000,000.

10-Q filing | 7.4M shares outstanding

8-K filing: NanoViricides, Inc. exchanged Old Warrants for an aggregate of 677,224 shares of Common Stock and warrants to purchase 347,222 shares of Common Stock at an exercise price of $3.00 per share.

8-K filing: NanoViricides, Inc. completed an underwritten public offering of 2,875,000 shares of common stock at $3.00 per share, resulting in net proceeds of approximately $7.78 million. ($8.63M proceeds)

S-1/A filing: The company is offering 2,500,000 shares of common stock in a firm commitment underwritten public offering based upon an assumed public offering price of $2.81 per share.

S-1/A filing: The filing is an S-1/A form for a firm commitment underwritten public offering of 2,500,000 shares of common stock, with an option for the underwriter to purchase up to an additional 375,000 shares, at an assumed price of $3.40 per share.